emalexadmin – License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders – Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today … Read more
– Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study – Chicago, Nov. 10, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded by Paragon Biosciences to develop treatments for central nervous system … Read more
– Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide – Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, is seeking people who stutter to … Read more
– Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs– Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical … Read more
– Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners – Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today … Read more